Row
T
TARSAI Stock Diagnostic Report
Form 4 Tarsus Pharmaceuticals Inc For: 29 June
The Form 4 submission by Tarsus Pharmaceuticals is not expected to provide significant volatility for investors.
View Source Article ↗
AI CATALYST SCORE20 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
TARS Analysis History (Last 30 Days)